<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To specify the incidence and risk factors for secondary <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> (ADs) after HSCT for a primary AD, we retrospectively analyzed AD patients treated by HSCT reported to EBMT from 1995 to 2009 with at least 1 secondary AD (cases) and those without (controls) </plain></SENT>
<SENT sid="1" pm="."><plain>After autologous HSCT, 29 of 347 patients developed at least 1 secondary AD within 21.9 (0.6-49) months and after allogeneic HSCT, 3 of 16 patients </plain></SENT>
<SENT sid="2" pm="."><plain>The observed secondary ADs included: <z:hpo ids='HP_0001890'>autoimmune hemolytic anemia</z:hpo> (n = 3), <z:e sem="disease" ids="C1096116" disease_type="Disease or Syndrome" abbrv="">acquired hemophilia</z:e> (n = 3), <z:hpo ids='HP_0001973'>autoimmune thrombocytopenia</z:hpo> (n = 3), <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (n = 2), <z:hpo ids='HP_0100646'>thyroiditis</z:hpo> (n = 12), blocking thyroid-stimulating hormone receptor antibody (n = 1), <z:hpo ids='HP_0100647'>Graves disease</z:hpo> (n = 2), <z:hpo ids='HP_0003473'>myasthenia</z:hpo> gravis (n = 1), <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (n = 2), <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e> (n = 2), <z:hpo ids='HP_0002633'>vasculitis</z:hpo> (n = 1), <z:hpo ids='HP_0003765'>psoriasis</z:hpo> (n = 1), and psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo> (n = 1) </plain></SENT>
<SENT sid="3" pm="."><plain>After autologous HSCT for primary AD, the cumulative incidence of secondary AD was 9.8% Â± 2% at 5 years </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0409974" disease_type="Disease or Syndrome" abbrv="">Lupus erythematosus</z:e> as primary AD, and antithymocyte globulin use plus CD34(+) graft selection were important risk factors for secondary AD by multivariate analysis </plain></SENT>
<SENT sid="5" pm="."><plain>With a median follow-up of 6.2 (0.54-11) years after autologous HSCT, 26 of 29 patients with secondary AD were alive, 2 died during their secondary AD (<z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, <z:e sem="disease" ids="C0684275,C0019069" disease_type="Disease or Syndrome" abbrv="">hemophilia</z:e>), and 1 <z:hpo ids='HP_0011420'>death</z:hpo> was HSCT-related </plain></SENT>
<SENT sid="6" pm="."><plain>This European multicenter study underlines the need for careful management and follow-up for secondary AD after HSCT </plain></SENT>
</text></document>